Snehal Gis: Gene Therapy Revolutionizing the Hemophilia Treatment Landscape
Snehal Gis, Senior Digital Analyst Manager and Senior Research Associate at Global Insight Services shared a post on LinkedIn:
”The Hemophilia Gene Therapy Market is entering a transformative phase, driven by the promise of long-term or potentially curative treatments for patients suffering from hemophilia, a rare genetic bleeding disorder.
Unlike traditional therapies that rely on frequent factor replacement infusions, gene therapy introduces functional copies of defective genes into a patient’s cells, enabling the body to produce clotting factors naturally.
This shift represents a paradigm change in treatment approaches, offering improved quality of life and reduced lifetime healthcare costs.
Click to Request a Sample of this Report for Additional Market Insights.”
Stay updated with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering